Paola Columpsi

Paola Columpsi

Auto-generated profile, based on publicly available information

Paola Columpsi

Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2016 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
PCPaola Columpsi
Paola Columpsi
PSPaolo Sacchi
Paolo Sacchi
VZValentina Zuccaro
Valentina Zuccaro
SCSerena Cima
Serena Cima
CSCristina Sarda
Cristina Sarda
Raffaele BrunoRaffaele Bruno
Raffaele Bruno


1 January 2015
Verified
Journal Article
Closed access
SNS Novati
S Novati
PSPaolo Sacchi
Paolo Sacchi
SCS Cima
S Cima
VZValentina Zuccaro
Valentina Zuccaro
PCP Columpsi
P Columpsi
Raffaele BrunoRaffaele Bruno
Raffaele Bruno

2 April 2016 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
VZValentina Zuccaro
Valentina Zuccaro
PCPaola Columpsi
Paola Columpsi
AAAlice Apollinari
Alice Apollinari
PSPaolo Sacchi
Paolo Sacchi
MMMarco Mussa
Marco Mussa
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations. Areas covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials. Expert opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.